- Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
- Ironwood Pharmaceuticals Reports First Quarter 2024 Results
- Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
- Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
- Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.49 |
---|---|
High | 6.50 |
Low | 6.09 |
Bid | 6.09 |
Offer | 6.10 |
Previous close | 6.49 |
Average volume | 2.59m |
---|---|
Shares outstanding | 158.96m |
Free float | 156.22m |
P/E (TTM) | -- |
Market cap | 1.03bn USD |
EPS (TTM) | -6.79 USD |
Data delayed at least 15 minutes, as of May 23 2024 20:26 BST.
More ▼